Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Martin Evans | M | 83 |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom.
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | 15 anni |
Ajan Reginald | M | 52 |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom.
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | 15 anni |
Darrin Disley | M | 57 |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom.
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Sabena Sultan | M | - |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Chaim Hurvitz | M | 64 |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | - |
Gary Pisano | M | 62 |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | - |
Stephen Westaby | M | - |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Harry Hoelzer | M | - |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Conor Kehoe | M | - |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | - |
Fiona Murray | M | - |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | - |
Lee Phillip Chapman | M | 48 |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Duncan Mark Powell Ribbons | M | 46 |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Nigel James Scott | M | 73 |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Regno Unito | 13 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- David Preston
- Contatti personali